5 days ago · Each cycle of treatment lasts 28 days (4 weeks). You continue having daratumumab, lenalidomide and dexamethasone for as long as the treatment is working, and ...

3 days ago · This booklet discusses Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone as treatment for newly diagnosed myeloma.

3 days ago · Use of low doses of the steroid dexamethasone in combination with Revlimid® (lenalidomide) provided significantly improved survival in multiple myeloma.

7 days ago · In the study, patients who received the Monjuvi combination achieved an investigator-assessed median progression-free survival of 22.4 months, compared to 13.9 ...

5 days ago · While multiple myeloma has no cure, it's possible to achieve remission. Learn what steps to take next if your treatment stops working.

6 days ago · 3. Pain. Many people with multiple myeloma have bone pain or pain related to their medications, such as lenalidomide (Revlimid). Pain may also be related to ...

5 days ago · Patients who achieved a complete remission experienced a subsequent median survival of 9.7 years compared with 4.4 years for patients who achieved partial ...

6 days ago · The median time to response was 0.79 months in the daratumumab group and 0.82 months in the control group, and the median time to best response was 4.9 months ...

2 days ago · This booklet describes the typical journey of a patient with myeloma in the US who might undergo ASCT.

2 days ago · Peter Martin, MD, discusses the current role of BTK inhibitors in MCL and how future research may solidify the use of these agents in this disease.